Lv31
220 积分 2023-10-19 加入
Anticancer drug CX-5461 exerts pangenotypic anti-hepatitis E virus effect in human liver organoids and animal models
27分钟前
求助中
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management
8天前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
29天前
已完结
International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update
1个月前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
1个月前
已完结
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist
2个月前
已完结
Design and Evaluation of Conformationally Locked Indole-Carboxylic Acids as Selective THRβ Agonists against MASH
2个月前
已完结
Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
3个月前
已完结
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial
3个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
5个月前
已完结
皖公网安备34019202002308
